Draft Recommendation Statement and Draft Evidence Review:

Medication Use to Reduce Risk of Breast Cancer

Public Comment on Draft Recommendation Statement and Draft Evidence Review: Medication Use to Reduce Risk of Breast Cancer

The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on medication use to reduce risk of breast cancer. Clinicians should offer risk-reducing medications to women at increased risk for breast cancer and at low risk for adverse medication effects. The draft recommendation statement and draft evidence review are available for review and public comment from January 15, 2019 to February 11, 2019 here.

The Draft Recommendation Statement and Draft Evidence Review Are Open to Public Comment

COMMENTING DETAILS

Public Comment Period:

1/15/19 - 2/11/19

Any visitor to the Task Force Web site can comment on any of the listed USPSTF draft documents. However, readers should note that the USPSTF writes these documents for researchers, primary care doctors, and other health care providers, using medical and scientific language as appropriate for these audiences.

DRAFT RECOMMENDATION SUMMARY

Population

Recommendation

Grade

Women at increased risk for breast cancer

The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects.

Women not at increased risk for breast cancer

The USPSTF recommends against the routine use of risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, in women who are not at increased risk for breast cancer.

See the full draft recommendation statement